Inclusion Criteria:

- Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO
classification). DLBCL with some small cell infiltration in bone marrow or lymph node
may be included.

- Aged over 80 years.

- Ann Arbor stage I bulky, II, III or IV

- Age-adjusted International Prognostic Index equal to 0, 1, 2 and 3.

- Patient non previously treated.

- ECOG performance status ≤ 2.

- With a minimum life expectancy of 3 months.

- Negative HIV, HBV and HCV serologies test ≤ 4 weeks (except after vaccination).

- Having previously signed a written informed consent

Exclusion Criteria:

- Any other histological type of lymphoma.

- Any history of treated or non-treated indolent lymphoma.

- Central nervous system or meningeal involvement by lymphoma.

- Contra-indication to any drug contained in the chemotherapy regimens.

- Any serious active disease (according to the investigator's decision).

- Poor renal function (creatinin level>150µmol/l), poor hepatic function (total
bilirubin level>30mmol/l, transaminases>2.5 maximum normal level) unless these
abnormalities are related to the lymphoma.

- Poor bone marrow reserve as defined by neutrophils <1.5 G/l or platelets <100 G/l,
unless related to bone marrow infiltration.

- Any history of cancer during the last 5 years with the exception of non-melanoma skin
tumors or stage 0 (in situ) cervical carcinoma.

- Treatment with any investigational drug within 30 days before planned first cycle of
chemotherapy and during the study.

- Adult patient under tutelage.